Cyclic peptide-N-acetylgalactosamine (GalNAc) conjugates for drug delivery to liver cells

Abstract

A conjugate comprising a cyclic peptide scaffold and one or more N-acetylgalactosamine (GalNAc) moieties. The conjugate may further carry a diagnostic or therapeutic agent for use in delivering a drug to liver cells. In some embodiments, the cyclic peptide may have 4-10 amino acid residues. The GalNAc moiety may be covalently attached to the cyclic peptide scaffold via a first linker, and the drug may be covalently attached to the cyclic peptide scaffold via a second linker.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of the filing date of International Patent Application No. PCT / CN2021 / 089305, filed April 23, 2021, the entire contents of which are incorporated herein by reference.

[0002] Reference to Electronically Submitted Sequence Listing The contents of the sequence listing in the electronically submitted ASCII text file (Name: 112319-0026-70002WO2_SEQ.txt, Size: 2,507 bytes, and Creation Date: April 19, 2022) filed with this application are incorporated herein by reference in their entirety. [Background technology]

[0003] N-acetylgalactosamine (GalNAc) has high binding affinity to the asialoglycoprotein receptor (ASGPR), which is highly expressed on hepatocytes, and therefore this moiety is commonly used to deliver therapeutic or diagnostic agents conjugated to the GalNAc moiety to liver cells.

[0004] GalNAc conjugation is one of the main approaches for delivering oligonucleotide-based therapeutics to liver cells.Multiple GalNAc-siRNA conjugate drug candidates are currently in clinical trials for treating a wide variety of diseases.Therefore, it is of great interest to develop an improved scaffold for preparing GalNAc-drug conjugates with high liver cell targeting efficiency and high endosomal escape efficiency, so that GalNAc-drug conjugates can enter cytoplasm and induce robust therapeutic effects. Summary of the Invention

[0005] The present disclosure is based at least in part on the development of a cyclic peptide-based scaffold for conjugating GalNAc moiety and a drug of interest.The GalNAc conjugate obtained by using such scaffold structure has shown high liver cell targeting efficiency and high endosomal escape efficiency.Therefore, it is expected that the cyclic peptide-based scaffold and the GalNAc conjugate prepared thereby can function as an effective drug delivery platform for targeting liver cells.

[0006] Thus, in some aspects, the present disclosure provides a conjugate comprising a cyclic peptide scaffold and one or more N-acetylgalactosamine (GalNAc) moieties. The cyclic peptide scaffold may contain 4-10 amino acid residues. In some embodiments, the cyclic peptide scaffold may contain 4-8 amino acid residues, e.g., 4-6 amino acid residues. In one example, the cyclic peptide consists of 6 amino acid residues. In some cases, the cyclic peptide contains Glu, Asp, Lys, Arg, or a combination thereof. For example, the cyclic peptide may contain at least one Glu residue and at least one Lys residue. In addition, the cyclic peptide may further contain Gly, Ala, or Val. The amino acid residues in the cyclic peptide may be in the D-form.

[0007] In some examples, the cyclic peptide scaffold has an amino acid sequence of Lys-Glu-Lys-Gly-Lys-Gly (SEQ ID NO: 5). Alternatively, the cyclic peptide scaffold has an amino acid sequence of Lys-Glu-Lys-Ala-Lys-Ala (SEQ ID NO: 6). One or more amino acid residues in the cyclic peptide scaffold can be in the D-form. In one example, the cyclic peptide scaffold has an amino acid sequence of Lys-Glu-Lys-βAla-Lys-βAla (SEQ ID NO: 7). Other exemplary cyclic peptide scaffolds include, but are not limited to, CPS-001, CPS-002, CPS-003, and CPS-031. See, e.g., Table 1 and Figures 13A-13D). In some cases, the exemplary cyclic peptide scaffold may be a functional equivalent of any one of CPS-001, CPS-002, CPS-003, and CPS-031, containing the same core structure (e.g., a cyclic peptide scaffold containing the same amino acid residues or isomers thereof and the same linker). The functional equivalent of any one of CPS-001, CPS-002, CPS-003, and CPS-031 (reference conjugate) may be a stereoisomer of the reference conjugate (e.g., a switch from S-enantiomer to R-enantiomer at one or more chiral centers). Alternatively or in addition, the functional equivalent may contain a different protecting group as the Cbz group in any one of CPS-001, CPS-002, CPS-003, and CPS-031.

[0008] In any of the conjugates disclosed herein, each of the GalNAc moieties can be covalently linked to the cyclic peptide scaffold via a first linker. In some cases, the cyclic peptide scaffold comprises one or more Lys residues, and each first linker can be covalently linked to at least one of the Lys residues. In some examples, each first linker can comprise a linear chain having 3-8 atoms, e.g., C, O, or a combination thereof. Specific examples of first linkers can be Gal-1, Gal-2, Gal-3, Gal-4, or Gal-5 linkers. See, e.g., Table 2.

[0009] Any of the conjugates disclosed herein may further include an agent (e.g., a therapeutic agent or a diagnostic agent) that may be covalently attached to the cyclic peptide scaffold via a second linker. In some cases, the cyclic peptide scaffold includes one or more Glu residues, and the second linker may be covalently attached to at least one of the Glu residues. In some examples, the second linker is a lipid linker. In other examples, the second linker can be a polyethylene glycol (PEG) linker. In yet other examples, the second linker can be an alkylamine linker.

[0010] In some examples, the conjugates disclosed herein may have the structure of formula (I): [ka] , Wherein T is a drug and L 1 is a first linker, the first linker can be a linker in Gal-1, Gal-2, Gal-3, Gal-4, or Gal-5; L 2 is the second linker.

[0011] In other examples, the conjugates disclosed herein may have the structure of formula (II): [ka] Wherein T is a drug and L 1 is a first linker, the first linker can be a linker in Gal-1, Gal-2, Gal-3, Gal-4, or Gal-5; L 2 is the second linker.

[0012] In some embodiments, the agent is a diagnostic agent. In other embodiments, the agent can be a therapeutic agent. In some instances, the agent is a small molecule. Alternatively, the agent is a nucleic acid, such as a small interfering RNA (siRNA), an antisense oligonucleotide (ASO), or a nucleic acid aptamer.

[0013] Specific examples of conjugates disclosed herein include 5-FAM-CPMB-0011, 5-FAM-CPMB-0012, 5-FAM-CPMB-0013, 5-FAM-CPMB-0014, 5-FAM-CPMB-0015, 5-FAM-CPMB-0021, 5-FAM-CPMB-0023, 5-FAM-CPMB-0025, 5-FAM-CPMB-0031, 5-FAM-CPMB-0033, 5-FAM-CPMB-0034, 5-FAM-CPMB-0035, 5-FAM-CPMB-0311, 5-FAM-CPMB-0313, CPMB-0013, CPMB-0023, CPMB-0013-DOTMr, or CPMB-0023-DOTMr.

[0014] In other aspects, the present disclosure provides a pharmaceutical composition comprising any of the conjugates disclosed herein and a pharma- ceutically acceptable excipient.

[0015] Further provided herein is a method of delivering a drug to liver cells, comprising contacting the liver cells with a conjugate disclosed herein or a composition comprising such. In some embodiments, the contacting step comprises administering the conjugate or a composition comprising such to a subject in need thereof. In other embodiments, the contacting step comprises incubating the conjugate or a composition comprising such with liver cells in vitro. In this case, the method may further comprise administering the liver cells to a subject in need thereof after contacting with the conjugate or composition.

[0016] Also within the scope of the present disclosure is any of the conjugates or compositions comprising such for use in the delivery of diagnostic or therapeutic agents to liver cells, and the use of such conjugates or compositions comprising such for the manufacture of a medicament for use in the diagnosis or treatment of liver disease.

[0017] The details of one or more embodiments of the invention are set forth in the description below. Other features and advantages of the invention will be apparent from the following drawings and certain detailed description, and from the appended claims. [Brief description of the drawings]

[0018] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, which may be better understood by reference to the drawings in combination with the specific detailed description presented herein. [Figure 1] FIG. 1 is a schematic diagram showing an exemplary synthetic scheme for producing CPMB-002. [Diagram 2] 2A includes schematic diagrams showing an exemplary synthetic scheme for producing 5-FAM-CPMB-0013. FIG 2A: An exemplary synthetic scheme for producing CPMB-0013-A. FIG 2B: An exemplary synthetic scheme for producing 5-FAM-CPMB-0013 from CPMB-0013-A. [Diagram 3] FIG. 1 is a schematic diagram showing an exemplary synthetic scheme for producing CPMB-0013. [Figure 4] FIG. 1 is a schematic diagram showing an exemplary synthetic scheme for producing CPMB-0013-DMTr. [Diagram 5] 5A includes schematic diagrams showing exemplary synthetic schemes for producing CPG-PEG4-CPMB-0013-DMTr. FIG. 5A: Exemplary synthetic scheme for producing CPG-PEG4. FIG. 5B: Exemplary synthetic scheme for producing CPG-PEG4-CPMB-0013-DMTr from CPG-PEG4. [Figure 6] 6A includes schematic diagrams showing an exemplary synthetic scheme for producing 5-FAM-CPMB-0023. FIG 6A: An exemplary synthetic scheme for producing CPMB-0023-A. FIG 6B: An exemplary synthetic scheme for producing 5-FAM-CPMB-0023 from CPMB-0023-A. [Figure 7]FIG. 1 is a schematic diagram showing an exemplary synthetic scheme for producing CPMB-0023. [Figure 8] FIG. 1 is a schematic diagram showing an exemplary synthetic scheme for producing CPMB-0023-DMTr. [Figure 9] FIG. 1 is a schematic diagram showing an exemplary synthetic scheme for producing CPG-PEG4-CPMB-0023-DMTr. [Figure 10] FIG. 1 shows the improved stability of cyclic peptide-tri-GalNAc conjugates compared to tri-GalNAc. [Figure 11] FIG. 1 shows endosomal escape of cyclic peptide-tri-GalNAc conjugates compared to tri-GalNAc. [Figure 12] FIG. 1 is an exemplary diagram showing the structure of a cyclic peptide-GalNAc conjugate disclosed herein. [Figure 13] Includes diagrams showing structures of representative cyclic peptide scaffolds attached to linkers. Figure 13A: CPS-001. Figure 13B: CPS-002. Figure 13C: CPS-003. Figure 13D: CPS-031. [Figure 14]Figures showing structures of representative cyclic peptide-GalNAc-drug conjugates are included. Figure 14A: 5-FAM-CPMB-0011. Figure 14B: 5-FAM-CPMB-0012. Figure 14C: 5-FAM-CPMB-0013. Figure 14D: 5-FAM-CPMB-0014. Figure 14E: 5-FAM-CPMB-0015. Figure 14F: 5-FAM-CPMB-0021. Figure 14G: 5-FAM-CPMB-0023. Figure 14H: 5-FAM-CPMB-0025. Figure 14I: 5-FAM-CPMB-0026. AM-CPMB-0031. Figure 14J: 5-FAM-CPMB-0033. Figure 14K: 5-FAM-CPMB-0034. Figure 14L: 5-FAM-CPMB-0035. Figure 14M: 5-FAM-CPMB-0311. Figure 14N: 5-FAM-CPMB-0313. Figure 14O: CPMB-0013. Figure 14P: CPMB-0023. Figure 14Q: 5-FAM-tri-GalNAc (positive control). Figure 14R: 5-FAM-CPMB-0031-Ac (negative control). Figure 14S: CPMB-0013-DOTMr. Figure 14T: CPMB-0023-DOTMr. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Provided herein is the development of cyclic peptide molecules that can serve as a scaffold for conjugating multiple copies (e.g., three) of N-acetylgalactosamine (GalNAc) moieties and an agent of interest (e.g., a therapeutic or diagnostic agent) to be delivered to liver cells. The GalNAc moiety and / or the agent of interest can be conjugated (e.g., covalently) to the cyclic peptide scaffold via a flexible linker. The flexible linker can be designed to minimize the interference between various GalNAc moieties and the agent of interest and maximize the binding affinity of the GalNAc moiety to ASGPR on liver cells. The exemplary cyclic peptide-GalNAc conjugates provided herein show high binding activity to liver cells and high endosomal escape rate, indicating that such cyclic peptide-GalNAc conjugates can effectively deliver an agent of interest (e.g., a nucleic acid-based agent such as a small interfering RNA, an antisense oligonucleotide, or a nucleic acid aptamer) into liver cells to exert its intended biological activity.

[0020] Accordingly, provided herein are cyclic peptide-GalNAc conjugates, pharmaceutical compositions comprising such, and methods of delivering diagnostic or therapeutic agents to liver cells using such conjugates.

[0021] I. Cyclic Peptide Scaffold-GalNAc Conjugates In some aspects, the disclosure provides cyclic peptide-GalNAc conjugates, each of which comprises a cyclic peptide scaffold with one or more GalNAc moieties (e.g., three) attached via a flexible linker (first linker). The conjugates may further comprise an agent of interest via a flexible linker (second linker).

[0022] Some of the compounds according to the present disclosure may exist as stereoisomers, i.e., have the same atomic connectivity of the covalently bonded atoms, but different spatial orientation of the atoms. For example, the compounds may be optical stereoisomers containing one or more chiral centers, and therefore may exist in two or more stereoisomeric forms (e.g., enantiomers or diastereomers). Thus, such compounds may exist as single stereoisomers (i.e., essentially free of other stereoisomers), racemates, and / or mixtures of enantiomers and / or diastereomers. As another example, stereoisomers include geometric isomers, such as cis or trans orientation of substituents on adjacent carbons of a double bond. Unless otherwise specified, all such stereoisomeric forms are included in the formulas provided herein.

[0023] Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by the (R) and (S) sequencing rules of Cahn and Prelog, or by the way in which a molecule rotates the plane of polarized light and is designated as dextrorotatory or levorotatory (i.e., as (+) or (-) isomer, respectively). Chiral compounds can exist as either individual enantiomers or mixtures thereof. A mixture containing equal proportions of enantiomers is termed a "racemic mixture". Unless otherwise indicated, the present specification is intended to include individual stereoisomers as well as mixtures. Methods for the determination of stereochemistry and separation of stereoisomers are well known in the art and can be found in, for example, ADVANCED ORGANIC CHEMISTRY, 6 th (See discussion in Chapter 4 of the above issue of the present disclosure, J. March, John Wiley and Sons, New York, 2007), differing in chirality at one or more stereocenters. All such single stereoisomers, racemates, and mixtures thereof are intended to be within the scope of this disclosure.

[0024] A. Cyclic Peptide Scaffolds The cyclic peptide scaffold used in any of the conjugates disclosed herein may contain 4 to 10 amino acid residues. In some cases, the cyclic peptide scaffold may contain 4 to 8 amino acid residues. In one example, the cyclic peptide scaffold disclosed herein contains 6 amino acid residues.

[0025] The cyclic peptide scaffolds disclosed herein may contain one or more amino acid residues whose side chains contain functional groups (e.g., -COOH, -NH2, -SH, or -OH). Such functional groups can be used in chemical reactions for covalent conjugation of a GalNAc moiety (e.g., via a linker) and / or an agent of interest (e.g., via a linker). For example, the cyclic peptide scaffolds disclosed herein may contain at least one Arg or Lys (e.g., Lys) residue whose -NH2 functional group in the side chain can be used for covalent conjugation of a GalNAc moiety or an agent of interest. In another example, the cyclic peptide scaffolds disclosed herein may contain at least one Asp or Glu residue whose -COOH functional group in the side chain can be used for covalent conjugation of a GalNAc moiety or an agent of interest.

[0026] In some embodiments, the cyclic peptide scaffold may contain at least two different types of amino acid residues (e.g., Lys and Glu residues) with different functional groups in their side chains to facilitate conjugation of the GalNAc moiety and the agent of interest. For example, the cyclic peptide scaffold may contain multiple Lys residues (e.g., three Lys residues), each of which may serve as an anchor for conjugating the GalNAc moiety, and one Asp or Glu amino acid residue that may serve as an anchor for conjugating the agent of interest.

[0027] Any of the cyclic peptide scaffolds disclosed herein may further contain one or more amino acid residues having an aliphatic side chain, such as Gly, Ala, Val, Ile, or Leu. In some examples, the cyclic peptide scaffold may contain Gly, Ala, or a combination thereof.

[0028] The amino acid residues in the cyclic peptide scaffold may be in the L-form, the D-form, or a mixture thereof. In some examples, the cyclic peptide scaffold may contain at least one amino acid residue in the D-form, e.g., one or more D-Ly or one D-Glu. Exemplary cyclic peptide scaffolds are provided in Table 1 below. Also see Figures 13A-13D for their chemical structures. [Table 1]

[0029] B. GalNAc-linker moiety The conjugates disclosed herein comprise any of the cyclic peptide scaffolds disclosed herein and one or more GalNAc moieties that can be covalently conjugated to the cyclic peptide scaffold via a flexible linker (first linker).

[0030] Any flexible linker can be used in making the conjugates disclosed herein. In some embodiments, the first linker can be a linear chain containing 3-8 atoms, which can be C, O, N, or a combination thereof. A first linker of such length can minimize interference between multiple GalNAc moieties and achieve overall binding affinity to liver cells.

[0031] Table 2 below provides exemplary GalNAc-linker structures for use in making the conjugates disclosed herein. The -COOH functional groups of Gal-1 through Gal-5 listed in Table 2 can be used to react with -NH2 functional groups in the cyclic peptide scaffold, resulting in covalent conjugation of the GalNAc linker moiety onto the cyclic peptide scaffold. [Table 2]

[0032] C. Drug of interest The conjugates disclosed herein may further comprise an agent of interest that may be conjugated (e.g., covalently) to the cyclic peptide scaffold via a second flexible linker. In some embodiments, the second flexible linker is different from the first flexible linker.

[0033] Any flexible linker can be used to conjugate the agent of interest to the cyclic peptide scaffold disclosed herein. Examples include, but are not limited to, lipid linkers, polyethylene glycol linkers, or aliphatic chain linkers. The second flexible linker can contain two functional groups (e.g., two different functional groups) at both ends, one functional group for reacting with the agent of interest and the other functional group for reacting with the cyclic peptide scaffold. For example, the second linker can contain a -NH2 functional group at one end that can be reached at the -COOH functional group in the cyclic peptide scaffold (e.g., in an Asp or Glu residue). The choice of functional group for linking the agent of interest will be determined by the type of agent, e.g., the functional groups contained therein, which is within the knowledge of a person skilled in the art.

[0034] The agent may be of any type, e.g., a small molecule, a peptide or polypeptide, an oligosaccharide, a lipid, or a nucleic acid (e.g., RNA or DNA (double-stranded or single-stranded)). In some embodiments, the agent of interest may be a therapeutic agent, e.g., a therapeutic agent for the treatment of liver disease. In other embodiments, the agent of interest may be a diagnostic agent, which may be further conjugated to a label capable of directly or indirectly emitting a detectable signal.

[0035] In some embodiments, the agent of interest conjugated to the cyclic peptide scaffold can be a nucleic acid, such as small interfering RNA, antisense oligonucleotide (RNA or DNA), messenger RNA, or nucleic acid-based aptamer. Any of these nucleic acids can contain non-naturally occurring nucleobases, sugars, or covalent internucleoside bonds (backbones). Such modified oligonucleotides confer desirable properties, such as enhanced cellular uptake, improved affinity to target nucleic acid, and increased in vivo stability.

[0036] In one example, the nucleic acid-based agents (e.g., siRNAs) described herein may have modified backbones, including those that retain a phosphorus atom (see, e.g., U.S. Pat. Nos. 3,687,808, 4,469,863, 5,321,131, 5,399,676, and 5,625,050) and those that do not have a phosphorus atom (see, e.g., U.S. Pat. Nos. 5,034,506, 5,166,315, and 5,792,608). Examples of phosphorus-containing modified backbones include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates, including 3'-alkylene phosphonates, 5'-alkylene phosphonates, and chiral phosphonates, phosphinates, phosphoramidates, including 3'-amino phosphoramidates and aminoalkyl phosphoramidates, thionophosphoramidates, thionoalkyl phosphonates, thionoalkyl phototriesters, selenophosphates, and boranophosphates with 3'-5' or 2'-5' bonds.Such backbones also include those with reverse polarity, i.e., 3' to 3', 5' to 5', or 2' to 2' bonds. Modified backbones that do not contain phosphorus atoms are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatom or heterocyclic internucleoside linkages. Such backbones include those with morpholino linkages (formed in part from the sugar portion of the nucleoside), siloxane backbones, sulfide, sulfoxide, and sulfone backbones, formacetyl and thioformacetyl backbones, methyleneformacetyl and thioformacetyl backbones, riboacetyl backbones, alkene-containing backbones, sulfamate backbones, methyleneimino and methylenehydrazino backbones, sulfonate and sulfonamide backbones, amide backbones, and other backbones with mixed N, O, S, and CH2 constituent moieties.

[0037] In another example, the nucleic acid-based agents (e.g., siRNA) described herein may include one or more substituted sugar moieties. Such substituted sugar moieties may include one of the following groups at the 2' position of the substituted sugar moiety: OH, F, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, O-alkynyl, S-alkynyl, N-alkynyl, and O-alkyl-O-alkyl. In these groups, the alkyl, alkenyl, and alkynyl can be substituted or unsubstituted C1-C10 alkyl or C2-C10 alkenyl and alkynyl. The substituted sugar moiety may also include a heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, RNA cleaving group, reporter group, intercalator, group for improving the pharmacokinetic properties of an oligonucleotide, or group for improving the pharmacodynamic properties of an oligonucleotide, at the 2' position of the substituted sugar moiety. Preferred substituted sugar moieties include those having 2'-methoxyethoxy, 2'-dimethylaminooxyethoxy, and 2'-dimethylaminoethoxyethoxy. See Martin et al., Helv. Chim. Acta, 1995, 78, 486-504.

[0038] Alternatively or additionally, the nucleic acid-based agent (e.g., siRNA) described herein can comprise one or more modified natural nucleobases (i.e., adenine, guanine, thymine, cytosine, and uracil).Modified nucleobases include those described in U.S. Patent No. 3,687,808; The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859; Kroschwitz, JI, ed. John Wiley & Sons, 1990; Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613; and Sanghvi, YS, Chapter 15, Antisense Research and Applications, pages 289-302, CRC Press, 1993.Some of these nucleobases are particularly useful for increasing the binding affinity of interfering RNA molecules to their target site. These include 5-substituted pyrimidines, 6-azapyrimidines, and N-2, N-6, and O-6 substituted purines (e.g., 2-aminopropyl-adenine, 5-propynyluracil, and 5-propynylcytosine; see Sanghvi, et al., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278).

[0039] Alternatively or additionally, the nucleic acid-based agent (e.g., siRNA) described herein may contain one or more locked nucleic acids (LNAs). LNAs, often referred to as access-restricted RNAs, are modified RNA nucleotides in which the ribose moiety is modified with an extra bridge connecting the 2' oxygen and the 4' carbon. This bridge "locks" the ribose in the 3'-endo (north) conformation that is often found in A-form duplexes.

[0040] In some examples, the agent may be an intermediate for further attachment or synthesis of a nucleic acid-based therapeutic or diagnostic agent. For example, the agent conjugated to the cyclic peptide scaffold may be a solid support (e.g., control pore glass or CPG) that can be conjugated to the cyclic peptide scaffold via a second linker. The second linker may be attached to the cyclic peptide scaffold via a ribose moiety that can carry a DMTO protection moiety. This conjugate can be used to add the desired nucleic acid agent using a nucleic acid synthesis device that adds nucleotide residues to the ribose moiety via normal nucleic acid synthesis. After synthesis of the nucleic acid agent covalently conjugated to the cyclic peptide scaffold, the final cyclic peptide-GalNAc-nucleic acid conjugate can be released from the solid support (e.g., CPG). See the examples below.

[0041] D. Exemplary GalNAc-Cyclic Peptide Conjugates The GalNAc-cyclic peptide conjugates disclosed herein can contain one or more GalNAc moieties (e.g., three) via any of the cyclic peptide scaffolds disclosed herein and any of the first linkers disclosed herein. The conjugates can further include a second linker, e.g., a linker disclosed herein, to which any of the agents of interest disclosed herein are attached (e.g., covalently).

[0042] Table 3 provides non-limiting examples of GalNAc-cyclic peptide conjugates disclosed herein, and see Figures 14A-P for their chemical structures. [Table 3]

[0043] In some examples, the exemplary GalNAc-cyclic peptide conjugates disclosed herein contain a CPS001 cyclic peptide scaffold or a functional equivalent disclosed herein, and a GalNAc linker of Gal-3. In other examples, the exemplary GalNAc-cyclic peptide conjugates disclosed herein contain a CPS002 cyclic peptide scaffold or a functional equivalent disclosed herein, and a GalNAc linker of Gal-3. In yet other examples, the exemplary GalNAc-cyclic peptide conjugates disclosed herein contain a CPS003 cyclic peptide scaffold or a functional equivalent disclosed herein, and a GalNAc linker of Gal-5.

[0044] E. Synthesis of GalNAc-cyclic peptide conjugates The above conjugates can be prepared by methods well known in the art and by the synthetic routes disclosed herein. The chemicals used in the synthetic routes can include, for example, solvents, reagents, catalysts, and protecting and deprotecting group reagents. The methods described herein can also further include steps of adding or removing suitable protecting groups before or after the steps specifically described herein to ultimately allow synthesis of the conjugate or its intermediates. In addition, the various synthetic steps can be carried out in an alternative order or sequence to obtain the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in the synthesis of applicable indole compounds are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989), T. W. Greene and P. G. Muts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley and Sons (1999), L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994), and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and subsequent editions.

[0045] Briefly, the GalNAc moiety coupled with a suitable linker disclosed herein can be synthesized according to conventional methods or methods disclosed herein. Separately, the cyclic peptide scaffold disclosed herein can be prepared according to conventional methods or methods disclosed herein. The GalNAc moiety and the cyclic peptide scaffold can be reacted under suitable conditions to form a covalent bond, thereby conjugating the GalNAc moiety to the cyclic peptide scaffold. A similar approach can be applied to conjugate a drug of interest to the cyclic peptide scaffold via a linker according to conventional methods or methods disclosed herein.

[0046] As a non-limiting example of the synthesis of GalNAc moiety, suitable lactone moiety can be hydrolyzed to generate terminal hydroxyl-substituted carboxylic acid.Carboxylic acid can be protected, and the free hydroxyl replaces the acetylated hydroxyl on the anomeric carbon of peracetylated N-glucoseamine.Then, the carboxylic acid can be deprotected to generate GalNAc coupling partner.

[0047] As a non-limiting example of the synthesis of cyclic peptides, peptides can be synthesized using known Fmoc-protected solid-phase peptide synthesis with side chains protected as necessary. Peptide synthesis can be followed by derivatization, C-terminal and N-terminal deprotection, and cyclization of the peptide. Derivatization involves adding an amine linker to a suitable side chain, for example, glutamic acid. The appropriate amino acid (e.g., lysine) side chain is deprotected, and a GalNAc coupling partner is attached using known peptide bond formation conditions. The amine linker is then used to conjugate a drug as desired.

[0048] An example of coupling a drug to an amine linker can be 4,4-dimethoxytrityl (DMTr), which can be used to synthesize oligonucleotide polymers. By attaching a DMTr group to the GalNAc cyclic peptide described above, the resulting conjugate can be used as a substrate for synthesizing oligonucleotides (e.g., siRNA) using an oligonucleotide synthesizer.

[0049] Exemplary synthetic schemes for the cyclic peptide-GalNAc conjugates disclosed herein, or any intermediates therein, are provided in the Examples below.

[0050] II. Pharmaceutical Compositions Any of the cyclic peptide-GalNAc conjugates disclosed herein, including diagnostic or therapeutic agents (e.g., nucleic acid-based agents such as siRNA molecules), can be formulated into suitable pharmaceutical compositions. The pharmaceutical compositions described herein can further include pharma- ceutically acceptable carriers, excipients, or stabilizers in the form of lyophilized formulations or aqueous solutions. Remington: The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Williams and Wilkins, Ed. KE Hoover. Such carriers, excipients, or stabilizers can enhance one or more properties of the active ingredients in the compositions described herein, such as biological activity, stability, bioavailability, and other pharmacokinetics and / or biological activities.

[0051] Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl or benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, benzoate, sorbate, and m-cresol); low molecular weight (less than about 10 residues) polypeptides; serum albumin, gelatin, or immunoglobulins. The surfactant may include proteins such as riboflavin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, serine, alanine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextran; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™ (polysorbates), PLURONICS™ (non-ionic surfactants), or polyethylene glycol (PEG).

[0052] In other examples, the pharmaceutical compositions described herein may be formulated in sustained release form. Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers, such as films or microcapsules, where the matrices are in the form of shaped articles. Examples of sustained release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and 7-ethyl-L-glutamate, non-degradable ethylene vinyl acetate, degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), sucrose acetate isobutyrate, and poly-D-(−)-3-hydroxybutyric acid.

[0053] Pharmaceutical compositions used for in vivo administration must be sterile. This can be accomplished, for example, by filtration through sterile filtration membranes. Therapeutic compositions are generally placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle, or a manually accessed sealed container.

[0054] The pharmaceutical compositions described herein may be in unit dosage form, e.g., a solid, solution or suspension, or a suppository, for administration by inhalation or insufflation, by intrathecal, intrapulmonary, or intracerebral routes, oral, parenteral, or rectal administration.

[0055] To prepare solid compositions, the main active ingredient can be mixed with pharmaceutical carriers, such as conventional tableting ingredients, such as cornstarch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, or gums, and other pharmaceutical diluents, such as water, to form a solid preformulation composition containing a homogeneous mixture of the compound of the present invention or a non-toxic pharma-ceutically acceptable salt thereof.When these preformulation compositions are referred to as homogeneous, this means that the active ingredient is evenly distributed throughout the composition, and thus the composition can be easily subdivided into equally effective unit dosage forms, such as powder collections, tablets, pills, and capsules.These solid preformulation compositions are then subdivided into unit dosage forms of the above-mentioned type, which contain a suitable amount of active ingredient in the composition.

[0056] Suitable surfactants include, inter alia, non-ionic agents such as polyoxyethylene sorbitan (e.g., TWEEN 20, 40, 60, 80, or 85) and other sorbitans (e.g., SPAN 20, 40, 60, 80, or 85). Compositions having surfactants conveniently contain 0.05 to 5% surfactant, and may be 0.1 to 2.5%. It will be appreciated that other ingredients, such as mannitol or other pharma- ceutically acceptable vehicles, may be added as required.

[0057] Suitable emulsions can be prepared using commercially available fat emulsions, such as INTRALIPIDS™, LIPOSYN™, INFONUTROL™, LIPOFUNDIN™, and LIPIPHYSAN™. The active ingredient may be dissolved in a premixed emulsion composition, or alternatively, the active ingredient may be dissolved in oil (e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil, or almond oil) and in an emulsion formed when mixed with phospholipids (e.g., egg phospholipids, soybean phospholipids, or soybean lecithin) and water. It will be appreciated that other ingredients, such as glycerol or glucose, may be added to adjust the osmolality of the emulsion. Suitable emulsions typically contain up to 20% oil, e.g., 5-20% oil.

[0058] Pharmaceutical compositions for inhalation or insufflation include solutions and suspensions in pharma- ceutically acceptable aqueous or organic solvents or mixtures thereof, as well as powders. Liquid or solid compositions may contain suitable pharma- ceutically acceptable excipients as described above. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. In some embodiments, the compositions are composed of particles ranging in size from 10 nm to 100 mm.

[0059] Compositions in pharma- ceutically acceptable solvents, preferably sterile, can be nebulized by the use of gases. Nebulized solutions can be breathed directly from the nebulizing device, or the nebulizing device can be attached to a face mask, tent, endotracheal tube, and / or intermittent positive pressure breathing machine (ventilator). Solution, suspension, or powder compositions can be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.

[0060] In some embodiments, any of the pharmaceutical compositions herein may further comprise a second therapeutic agent, based on the intended therapeutic use of the composition.

[0061] III. Delivery of drugs to liver cells Any of the cyclic peptide-GalNAc conjugates disclosed herein can be used to deliver a target agent (e.g., a diagnostic or therapeutic agent) carried by the conjugate to liver cells either in vitro or in vivo.Therefore, a method for delivering a target agent to liver cells is provided herein, comprising contacting any of the cyclic peptide-GalNAc conjugates disclosed herein with liver cells to allow the agent carried by the conjugate to be delivered to liver cells.

[0062] In some embodiments, the contacting step can be carried out in vitro, for example in a cell culture system. For example, an effective amount of the cyclic peptide-GalNAc conjugate disclosed herein can be incubated with liver cells under suitable culture conditions for a suitable period of time, allowing the uptake of the conjugate by liver cells via the interaction between the GalNAc moiety and the ASGPR receptor on the liver cells. The liver cells containing the conjugate can be enriched and / or expanded. Such liver cells can be administered to a subject to treat a target disease, for example, one disclosed herein.

[0063] Alternatively, any of the cyclic peptide-GalNAc conjugates disclosed herein, or a pharmaceutical composition comprising such, may be administered to a subject in need of treatment via a suitable route.

[0064] To carry out the methods disclosed herein, an effective amount of the pharmaceutical composition described herein can be administered to a subject (e.g., a human) in need of treatment via a suitable route, for example, intravenous administration, e.g., as a bolus, or by continuous infusion over a period of time via intramuscular, intraperitoneal, intratumoral, intracerebrospinal, subcutaneous, intraarticular, intrasynovial, intratracheal, oral, inhalation, or topical routes. Commercially available nebulizers for liquid formulations, including jet nebulizers and ultrasonic nebulizers, are useful for administration. Liquid formulations can be directly nebulized, and lyophilized powders can be nebulized after reconstitution. Alternatively, the antibodies described herein can be aerosolized using fluorocarbon formulations and metered dose inhalers, or inhaled as lyophilized and milled powders.

[0065] The subject treated by the methods described herein can be a mammal, more preferably a human.Mammals include, but are not limited to, livestock, sport animals, pets, primates, horses, dogs, cats, mice and rats.The human subject in need of treatment can be a human patient who has, is at risk of, or is suspected of having a target disease / disorder, for example, a liver disease, such as liver cancer. Examples of such target diseases / disorders include acute hepatic porphyria, Alagille syndrome, alcohol-related liver disease, alpha-1 antitrypsin deficiency, autoimmune hepatitis, benign liver tumors, biliary atresia, cirrhosis, Crigler-Najjar syndrome, galactosemia, Gilbert's syndrome, hemochromatosis, hepatic encephalopathy, hepatitis A, hepatitis B, hepatitis C, hepatorenal syndrome, intrahepatic cholestasis of pregnancy (ICP), lysosomal acid lipase deficiency (LAL-D), liver cysts, liver cancer, neonatal jaundice, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), progressive familial intrahepatic cholestasis (PFIC), Reye's syndrome, glycogen storage disease type I, and Wilson's disease.

[0066] Subjects with the target disease may be identified by routine medical examination, e.g., laboratory tests, organ function tests, CT scans, or ultrasound. In some embodiments, the subject treated by the methods described herein may be a human cancer patient who has undergone or is undergoing another therapy, e.g., an anti-cancer therapy, e.g., chemotherapy, radiation therapy, immunotherapy, or surgery.

[0067] A subject suspected of having any of such target diseases / disorders may exhibit one or more symptoms of the disease / disorder. A subject at risk for a disease / disorder may have one or more risk factors for that disease / disorder.

[0068] As used herein, "effective amount" refers to the amount of each active agent required to confer a therapeutic effect on a subject, either alone or in combination with one or more other active agents. Determining whether an amount of a conjugate achieves a therapeutic effect will be apparent to one of skill in the art. Effective amounts will vary, as recognized by those of skill in the art, depending on the particular condition being treated, the severity of the condition, individual patient parameters including age, health, size, sex, and weight, duration of treatment, nature of concurrent therapy (if any), the particular route of administration, and similar factors within the knowledge and expertise of the medical practitioner. These factors are well known to those of skill in the art and can be addressed with only routine experimentation. In general, it is preferred to use the maximum dose of each component or combination thereof, i.e., the highest safe dose according to sound medical judgment.

[0069] Empirical considerations such as half-life generally contribute to the determination of dosage. For example, antibodies compatible with the human immune system, such as humanized or fully human antibodies, may be used to extend the half-life of the conjugate, particularly the drug of interest contained therein, and to prevent the conjugate from being attacked by the host's immune system. The frequency of administration may be determined and adjusted over the course of therapy, generally, but not necessarily, based on the treatment and / or suppression and / or remission and / or delay of the target disease / disorder. Alternatively, sustained continuous release formulations of the conjugates disclosed herein may be appropriate. Various formulations and devices for achieving sustained release are known in the art.

[0070] In one example, the dosage for the conjugates described herein can be empirically determined in an individual given one or more doses of the conjugate. The individual is given increasing doses of the agonist. To assess the efficacy of the agonist, indicators of disease / disorder can be tracked.

[0071] For purposes of this disclosure, the appropriate dosage of the cyclic peptide-GalNAc conjugates described herein will depend on the particular conjugate, particularly the particular drug of interest carried by the conjugate, the type and severity of the disease / disorder, whether the conjugate is administered for prevention or treatment, previous therapy, the patient's clinical history and response to the agonist, and the discretion of the attending physician. Typically, the clinician will administer the conjugate until a dosage is reached that achieves the desired result. Methods for determining whether a dosage has produced the desired result will be apparent to those of skill in the art. Administration of one or more conjugates may be continuous or intermittent, depending, for example, on the physiological state of the recipient, whether the purpose of administration is therapeutic or preventative, and other factors known to the skilled practitioner. Administration of the conjugates disclosed herein may be essentially continuous over a preselected period of time, or may be in a series of spaced doses, for example, either before, during, or after the onset of the target disease or disorder.

[0072] As used herein, the term "treating" refers to the application or administration of a composition comprising one or more active agents to a subject having a target disease or disorder, a symptom of a disease / disorder, or a predisposition to a disease / disorder, for the purpose of curing, curing, alleviating, mitigating, altering, remediating, ameliorating, improving, or affecting the disorder, the symptom of the disease, or the predisposition to the disease or disorder.

[0073] Alleviating the target disease / disorder includes delaying the onset or progression of the disease, or reducing disease severity, or prolonging survival. Alleviating the disease or prolonging survival does not necessarily require a curative outcome. As used herein, "delaying" the onset of the target disease or disorder means to postpone, prevent, slow, retard, stabilize, and / or prolong the progression of the disease. This delay can be of various lengths of time, depending on the disease history and / or the individual being treated. A method of "delaying" or alleviating the onset of a disease or delaying the onset of a disease is a method that reduces the probability of developing one or more symptoms of the disease within a given time frame and / or reduces the severity of symptoms within a given time frame when compared to not using the method. Such comparisons are typically based on clinical studies using a sufficient number of subjects to obtain statistically significant results.

[0074] "Onset" or "progression" of a disease refers to early signs and / or subsequent progression of the disease. Onset of a disease can be detectable and can be assessed using standard clinical techniques well known in the art. However, onset also refers to progression, which can be undetectable. For purposes of this disclosure, onset or progression refers to the biological course of a symptom. "Onset" includes onset, recurrence, and onset. As used herein, "onset" or "onset" of a target disease or disorder includes initial onset and / or recurrence.

[0075] Conventional methods known to those skilled in the art of medicine can be used to administer the pharmaceutical composition to a subject, depending on the type of disease or site of disease to be treated. The composition can also be administered via other conventional routes, for example, orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, intravaginally, or via an implanted reservoir. As used herein, the term "parenteral" includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques. In addition, the composition can be administered to a subject via an injectable depot administration route, for example, using 1, 3, or 6 month depot injectable or biodegradable materials and methods. In some examples, the pharmaceutical composition is administered intraocularly or intravitreally.

[0076] Injectable compositions may contain various carriers, such as vegetable oils, dimethylactamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, and polyols, such as glycerol, propylene glycol, and liquid polyethylene glycol. For intravenous injection, water-soluble antibodies may be administered by drip infusion, whereby a pharmaceutical formulation containing the conjugate and a physiologically acceptable excipient is infused. The physiologically acceptable excipient may include, for example, 5% dextrose, 0.9% saline, Ringer's solution, or other suitable excipient. Intramuscular preparations may be administered dissolved in a pharmaceutical excipient, such as water for injection, 0.9% saline, or 5% glucose solution.

[0077] In one embodiment, the conjugates disclosed herein can be administered by site-specific or targeted local delivery techniques. Examples of site-specific or targeted local delivery techniques include various implantable depot sources of the conjugates, or local delivery catheters, such as injection catheters, indwelling catheters, or needle catheters, synthetic grafts, adventitial wraps, shunts and stents, or other implantable devices, site-specific carriers, direct injection, or direct application. See, for example, WO 00 / 53211 and U.S. Patent No. 5,981,568.

[0078] Efficacy of treatment for a target disease / disorder can be assessed by methods well known in the art.

[0079] Kits for use in treating a disease The present disclosure also provides a kit for use in delivering an agent of interest (e.g., a diagnostic or therapeutic agent) to liver cells in vitro or in vivo, and / or for treating or alleviating a target disease.Such a kit can include one or more containers containing a cyclic peptide-GalNAc conjugate, such as any of those described herein.In some cases, the conjugates disclosed herein can be used together with a second therapeutic agent.

[0080] In some embodiments, the kit can include instructions for use according to any of the methods described herein. The included instructions can include instructions for administration of the conjugate and, optionally, a second therapeutic agent to treat, delay onset, or alleviate the target disease as described herein. The kit can further include instructions for selecting an individual suitable for treatment based on identifying whether the individual has the target disease, for example, applying the diagnostic method described herein. In yet other embodiments, the instructions include instructions for administering the conjugate as disclosed herein to an individual at risk for the target disease.

[0081] The instructions for use of the cyclic peptide-GalNAc conjugate generally include information regarding dosage, administration schedule, and route of administration for the intended treatment. The container may be a unit dose, bulk package (e.g., a multi-dose package), or sub-unit dose. The instructions provided in the kit of the present invention are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), although machine-readable instructions (e.g., instructions carried on a magnetic or optical memory disk) are also acceptable.

[0082] The label or package insert indicates that the composition is used for treating, delaying the onset of, and / or ameliorating a liver disease, e.g., liver cancer, etc. Instructions for performing any of the methods described herein can be provided.

[0083] The kit of the present invention is in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, and flexible packaging (e.g., sealed Mylar or plastic bags), etc. Also contemplated are packages for use in combination with certain devices, such as inhalers, nasal administration devices (e.g., atomizers), or injection devices, such as mini-pumps. The kit can have a sterile access port (e.g., the container can be an intravenous solution bag or vial with a stopper that can be pierced by a hypodermic needle). The container can also have a sterile access port (e.g., the container can be an intravenous solution bag or vial with a stopper that can be pierced by a hypodermic needle). At least one active agent in the composition is a cyclic peptide-GalNAc conjugate as described herein.

[0084] The kit may optionally provide additional components such as buffers and interpretive information. Typically, the kit comprises a container and a label or package insert on or associated with the container. In some embodiments, the invention provides an article of manufacture comprising the contents of the kit described above.

[0085] Common techniquesThe practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of those in the art. Such techniques are described in Molecular Cloning: A Laboratory Manual, second edition (Sambrook, et al., 1989) Cold Spring Harbor Press, Oligonucleotide Synthesis (MJ Gait, ed. 1984), Methods in Molecular Biology, Humana Press, Cell Biology: A Laboratory Notebook (JECellis, ed., 1989) Academic Press, Animal Cell Culture (RIFreshney, ed. 1987), Introuction to Cell and Tissue Culture (JP Mather and PE Roberts, 1998) Plenum Press, Cell and Tissue Culture: Laboratory Procedures (A. Doyle, JBGriffiths, and DG Newell, eds. 1993-8) J. Wiley and Sons, Methods in Enzymology (Academic Press, Inc.), Handbook of Experimental Immunology (DMWeir and CCBlackwell, eds.), Gene Transfer Vectors for Mammalian Cells (JMMiller and MP Calos, eds., 1987), Current Protocols in Molecular Biology (FMAusubel, et al. eds. 1987), PCR: The Polymerase Chain Reaction, (Mullis, et al., eds. 1994), Current Protocols in Immunology (JEColigan et al., eds., 1991), Short Protocols in Molecular Biology (Wiley and Sons, 1999), Immunobiology (C.A. Janeway and P. Travers, 1997), Antibodies (P. Finch, 1997), Antibodies: a practice approach (D. Catty., ed., IRL Press, 1988 - 1989), Monoclonal antibodies: a practical approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000), Using antibodies: a laboratory manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999), The Antibodies (M. Zanetti and J.D. Capra, eds. Harwood Academic Publishers, 1995), DNA Cloning: A practical Approach, Volumes I and II (D.N. Glover ed. 1985), Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins, eds.

Number

Number

Number

Number

[0086] Without further elaboration, it is believed that one skilled in the art can utilize the present invention to its fullest extent based on the above description. The following specific embodiments are therefore to be construed as merely illustrative, and not limiting of the remainder of the disclosure in any way. All publications mentioned herein are incorporated by reference for the purpose or subject matter referred to herein.

[0087] Example 1: Synthesis of L-Fmoc-Glu(Linker-Cbz)-OH and D-Fmoc-Glu(Linker-Cbz)-OH A: L-Fmoc-Glu(linker-Cbz)-OH Step 1: tert-Butyl N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 5 Synthesis of -(6-(((benzyloxy)carbonyl)amino)hexyl)-L-glutamate (Compound-1) [ka] An exemplary synthesis scheme for Compound-1 is provided above. A brief description is provided below.

[0088] To a solution of (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-5-oxopentanoic acid (10.0 g, 23.5 mmol, 1.0 equiv.) in DMF (40 mL) was added HATU (8.9 g, 23.5 mmol, 1.0 equiv.), DIPEA (12.3 mL, 70.5 mmol, 3.0 equiv.), and HOAt (3.2 g, 23.5 mmol, 1.0 equiv.). The resulting mixture was stirred at 25° C. for 10 min. Once the mixture became a homogeneous solution, benzyl (6-aminohexyl)carbamate hydrochloride (8.1 g, 28.2 mmol, 1.2 equiv.) was added and the resulting solution was stirred at 25° C. for 2 h. The progress of the reaction was monitored by LCMS. Upon completion, the solution was diluted with EtOAc (100 mL) and washed with brine (3×40 mL). The organic layer was dried over Na2SO4, filtered, concentrated in vacuo, and the crude product was used directly in the next step (yellow solid, 15.5 g). LCMS: (ESI) m / z=658.2 [M+H] + . Step 2:N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 5 -(6-(((benzyloxy)carbonyl)amino)hexyl)-L-glutamine (L-Fmoc-Glu(linker-Cbz)-OH) [ka]

[0089] An exemplary synthesis scheme for L-Fmoc-Glu(Linker-Cbz)-OH is provided above. A brief description is provided below.

[0090] To a solution of compound 1 (15.5 g, 23.5 mmol) in DCM (150 mL) was added 60 mL of TFA / TIS / / HO (10 / 1 / 1) and the resulting solution was stirred at 25 °C overnight and monitored by LCMS. Upon completion, the solution was concentrated in vacuo and the residue was purified by reverse phase chromatography eluting with HO (0.01% v / v TFA) / MeCN (95 / 5 to 5 / 95). This afforded 7.0 g (50% yield) of L-Fmoc-Glu(Linker-Cbz)-OH as a white solid. LCMS: (ESI) m / z=602.3 [M+H] + .

[0091] B: D-Fmoc-Glu(linker-Cbz)-OH The same procedure as above was used to synthesize D-Fmoc-Glu(Linker-Cbz)-OH. Also see the exemplary synthesis scheme below. 10.0 g of D-Fmoc-Glu-OtBu gave 5.7 g of D-Fmoc-Glu(Linker-Cbz)-OH, with a total yield of 40%. LCMS: (ESI) m / z=602.1 [M+H] + . [ka]

[0092] Example 2: Synthesis of CPMB-001 Step 1: 2 -N 2 -(N 5 -(6-(((benzyloxy)carbonyl)amino)hexyl)-N 2 -(N 6 -(tert-Butoxycarbonyl)-L-lysyl)-L-glutaminyl)-N 6 -(tert-Butoxycarbonyl)-L-lysylglycyl-N 6 Synthesis of -(tert-butoxycarbonyl)-L-lysylglycine (CPMB-001-A) [ka] The compounds were synthesized by standard solid phase peptide synthesis using the Fmoc strategy.

[0093] After swelling 2-Cl-CTC resin (5.0 g, 1.1 mmol / g, GL Biochem) in DMF for 10 min, the first amino acid Fmoc-Gly-OH (743 mg, 2.5 mmol) was coupled to the resin using DIPEA (1292 mg, 10 mmol) in DMF (80 mL) for 4 h at room temperature. The resin was washed with DCM and deactivated excess chloride with MeOH / DCM (1 / 1, 80 mL) for 1 h. The resin was washed with DMF. The resulting resin was treated with 20% piperidine / DMF (50 mL) for 20 min to remove the Fmoc group. The resulting resin was washed with DMF and treated with a solution of Fmoc-Lys(Boc)-OH (1874 mg, 4.0 mmol), HBTU (1517 mg, 4.0 mmol), HOBt (540 mg, 4 mmol), and DIPEA (1034 mg, 8.0 mmol) in DMF (80 mL) for 1 h at room temperature, thereby introducing Lys to give Fmoc-Lys(Boc)-Gly-CTC resin. Gly, Lys(Boc), Glu(tBu), and Lys(Boc) were introduced in a similar manner to give NH2-Lys(Boc)-Glu(Linker-Cbz)-Lys(Boc)-Gly-Lys(Boc)-Gly-CTC resin (SEQ ID NO: 8). The linear peptide was cleaved from the resin using cold HFIP / DCM (3 / 7, 100 mL), the mixed solution was added to the above dried resin, and the mixture was shaken for 1.0 h. The resin was filtered and washed with DCM (10 mL x 3). The filtrates were combined and the solvent was removed under vacuum. The crude peptide was dissolved in H2O / CH3CN and lyophilized to remove the remaining solvent. The linear peptide CPMB-001-A was collected as a white solid (1200 mg, crude). LCMS: (ESI) m / z=540.0[M+2H] / 2 + Step 2: Synthesis of benzyl (6-(3-((2S,5S,11S,17S)-5,11,17-tris(4-((tert-butoxycarbonyl)amino)butyl)-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexazacyclooctadecan-2-yl)propanamido)hexyl)carbamate (CPMB-001-B) [ka]

[0094] An exemplary synthetic scheme for producing CPMB-001-B from CPMB-001-A is provided above. Below is a brief description of the synthetic procedure.

[0095] HBTU (774 mg, 2.04 mmol, 2.0 equiv) was dissolved in DMF (20 mL) and DIEA (168 μL) was added. Then, a solution of CPMB-001-A (1200 mg, 1.02 mmol, 1.0 equiv) and DIEA (506 μL) in DMF (150 mL) was added dropwise to the HBTU solution at room temperature over 2 h. A brown mixture was obtained and LCMS showed complete conversion of CPMB-001-A. The reaction was then quenched by adding water (170 mL). The resulting mixture was extracted with ethyl acetate (200 mL×3). The organic layer was washed with NaCl solution (brine 100 mL and water 100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to give a light brown oil. The oil was triturated in water (100 mL) and filtered. The residue was triturated again in n-hexane (100 mL containing 5% ethyl acetate) for 2 h and filtered to give the target cyclic peptide as a pale yellow solid (742 mg, yield: 62.7%). LCMS: (ESI) m / z=1162.9 [M+H] + .

[0096] Step 3: Synthesis of benzyl (6-(3-((2S,5S,11S,17S)-5,11,17-tris(4-aminobutyl)-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexazacyclooctadecan-2-yl)propanamido)hexyl)carbamate (CPMB-001) [ka] An exemplary synthetic scheme for producing CPMB-001 from CPMB-001-B is provided above. Below is a brief description of the synthetic procedure.

[0097] CPMB-001-B (742 mg, 0.64 mmol) was dissolved in DCM (1 mL) and cooled to -5 °C, followed by the addition of ice-cold TFA / DCM (2 mL, v:v = 1:1). The solution was stirred at -5 °C for 1 h and the reaction was monitored by LCMS. After complete conversion of CPMB-001-B, ice-cold MTBE (40 mL) was added, producing a white precipitate. The suspension was centrifuged at 3200 r / min for 3 min and the supernatant was poured off. The precipitate was washed with MTBE (40 mL x 2) and centrifuged twice more. The white residue was dried under reduced pressure to give the target compound (CPMB-001) as a white solid (760 mg salt, yield: 98.8%). LCMS: (ESI) m / z=860.3 [M+H] + .

[0098] Example 3: Synthesis of CPMB-002 and CPMB-003 The same procedure was used for the synthesis of CPMB-002, see exemplary synthetic scheme in Figure 1.

[0099] 5.0 g (1.1 mmol) of CTC resin gave 700 mg of CPMB-002, for a total yield of 50%. LCMS: (ESI) m / z=860.3 [M+H] + .

[0100] From 5.0 g (1.1 mmol) of CTC resin, 781 mg of CPMB-003 was obtained, for a total yield of 65.0%. LCMS: (ESI) m / z=860.3 [M+H] + .

[0101] Example 4: Synthesis of Gal-1 Gal-1: 5-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)pentanoic acid (Gal-1). [ka]

[0102] An exemplary synthetic scheme for Gal-1 is provided above.

[0103] Steps 1 and 2: Synthesis of sodium 5-hydroxypentanoate (compound 3) and benzyl 5-hydroxypentanoate (compound 4) A mixture of tetrahydro-2H-pyran-2-one (10.0 g, 99.9 mmol, 1.0 equiv) and NaOH (4.0 g, 99.9 mmol, 1.0 equiv) was dissolved in H2O (100 mL). The solution was refluxed at 100° C. overnight and monitored by LCMS. Upon completion, the solution was concentrated in vacuo. The resulting white solid was taken up in acetone (200 mL) and nBu4NI (1.8 g, 5.0 mmol, 5 mol%) and benzyl bromide (14.2 mL, 119.9 mmol, 1.2 equiv) were added in sequence. The mixture was refluxed at 60° C. overnight and monitored by LCMS. Upon completion, the solution was concentrated in vacuo. The following residue was dissolved in EtOAc (150 mL) and washed with aqueous NaHSO4 (10.0 g in 150 mL H2O). The aqueous layer was then extracted with EtOAc (3×50 mL). The combined organic layers were washed with saturated aqueous NaHCO3 (100 mL), brine (40 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column eluted with PE / EtOAc (8 / 2). This gave 17.9 g (86% yield) of benzyl 5-hydroxypentanoate (compound 4) as a colorless oil. LCMS: (ESI) m / z=209.1 [M+H] + .

[0104] Step 3: Synthesis of (2R,3R,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-((5-(benzyloxy)-5-oxopentyl)oxy)tetrahydro-2H-pyran-3,4-diyl diacetate (compound 5) To a suspension of (2S,3R,4R,5R,6R)-3-acetamido-6-(acetoxymethyl)tetrahydro-2H-pyran-2,4,5-triyl triacetate (10.0 g, 25.7 mmol, 1.0 equiv.) in dry DCE (200 mL) was added trimethylsilyl trifluoromethanesulfonate (7.0 mL, 38.5 mmol, 1.5 equiv.). The mixture was stirred at 25° C. for 2 h, followed by compound 4 (7.5 g, 36.0 mmol, 1.4 equiv.) and 4A molecular sieves (5.0 g). The mixture was stirred overnight at 25° C. and monitored by LCMS. Upon completion of the reaction, the mixture was filtered to remove the 4A molecular sieves. The filtrate was added with saturated aqueous NaHCO3 (50 mL) and extracted with DCM (3×50 mL). The combined organic layers were washed with brine (40 mL), dried over Na2SO4, filtered and concentrated in vacuo. The resulting yellow oil was used directly for the next step. LCMS: (ESI) m / z=538.0 [M+H] + .

[0105] Step 4: Synthesis of 5-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)pentanoic acid (Gal-1) To a solution of compound 5 in MeOH / EtOAc (10.0 mL / 30.0 mL) was added Pd / C (1.0 g, 10.0%). The flask was evacuated and flushed with H2 three times. The suspension was stirred at 25 °C overnight and monitored by LCMS. Upon completion, the solution was filtered and concentrated in vacuo. The residue was purified by reverse phase chromatography eluting with HO (0.01% v / v TFA) / MeCN (95 / 5 to 5 / 95). This afforded 7.4 g (64% yield) of Gal-1 as a white foam. LCMS: (ESI) m / z=448.0 [M+H] + . 1H NMR(400 MHz,DMSO)δ 12.02(br,1H),7.82(d,J=9.2 Hz,1H),5.21(d,J=3.4 Hz,1H),4.96(dd,J=11.2,3.4 Hz,1H),4.48(d,J=8.5 Hz,1H),4.03(s,3H),3.88(dt,J=11.2,8.9 Hz,1H),3.73-3.66(m,1H),3.46-3.37(m,1H),2.20(t,J=7.1 Hz,2H),2.11(s,3H),2.00(s,3H),1.89(s,3H),1.77(s,3H),1.54-1.43(m,4H).

[0106] Example 5: Synthesis of Gal-2 Gal-2: Synthesis of 3-(2-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethoxy)propanoic acid (Gal-2) The same procedure is used in the synthesis of Gal-1. An exemplary synthesis scheme is provided below. 5.1 g (43.9 mmol) of 1,4-dioxepan-5-one gave 0.8 g of Gal-2, with an overall yield of 4.1%. [ka] LCMS: (ESI) m / z=464.4 [M+H] + .

[0107] Example 6: Synthesis of Gal-3 Gal-3: Synthesis of 4-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)butanoic acid (Gal-3) The same procedure was used in the synthesis of Gal-1. The synthetic scheme is provided below. 15.0 g (174.2 mmol) of dihydrofuran-2(3H)-one gave 3.9 g of Gal-3 as a white foam, with an overall yield of 5.2%. [ka] LCMS: (ESI) m / z=434.2 [M+H] + . 1 H NMR(400 MHz,DMSO)δ 12.03(br,1H),7.83(d,J=9.2 Hz,1H),5.75(s,1H),5.21(d,J=3.4 Hz,1H),4.95(dd,J=11.3,3.4 Hz,1H),4.47(d,J=8.5 Hz,1H),4.07-3.98(m,3H),3.87(dt,J=11.3,8.9 Hz,1H),3.70(dt,J=10.0,6.1 Hz,1H),2.23(t,J=7.4 Hz,2H),2.10(s,3H),1.99(s,3H),1.89(s,3H),1.77(s,3H),1.72-1.64(m,2H).

[0108] Example 7: Synthesis of Gal-4 Gal-4: Synthesis of 6-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexanoic acid (Gal-4) The same procedure is used in the synthesis of Gal-1. An exemplary synthesis scheme is provided below. 11.4 g (99.9 mmol) of oxepan-2-one gave 10.6 g of Gal-4 as a white foam, with an overall yield of 23%. [ka] LCMS: (ESI) m / z=462.2 [M+H] + . 1H NMR(400 MHz,DMSO)δ 12.07(br,1H),7.82(d,J=9.2 Hz,1H),5.21(d,J=3.4 Hz,1H),4.96(dd,J=11.2,3.4 Hz,1H),4.48(d,J=8.5 Hz,1H),4.05-4.01(m,3H),3.87(dt,J=11.2,8.9 Hz,1H),3.69(dt,J=9.9,6.4 Hz,1H),3.41(dt,J=9.9,6.4 Hz,1H),2.18(t,J=7.4 Hz,2H),2.11(s,3H),2.00(s,3H),1.89(s,3H),1.77(s,3H),1.54-1.41(m,4H),1.30-1.24(m,2H).

[0109] Example 8: Synthesis of Gal-5 Gal-5: Synthesis of 3-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)propanoic acid (Gal-5) The same procedure is used in the synthesis of Gal-1. An exemplary synthesis scheme is provided below. 6.5 g (36 mmol) of benzyl 3-hydroxypropanoate gave 4.3 g of Gal-5 as a white foam, with an overall yield of 28.5%. [ka] LCMS: (ESI) m / z=420.0 [M+H] + . 1 H NMR(400 MHz,DMSO)δ 12.27(br,1H),7.77(d,J=9.2 Hz,1H),5.21(d,J=3.4 Hz,1H),4.96(dd,J=11.2,3.4 Hz,1H),4.53(d,J=8.5 Hz,1H),4.08-3.98(m,3H),3.92-3.80(m,2H),3.68(dt,J=10.3,6.4 Hz,1H),2.46(t,J=6.4 Hz,2H),2.10(s,3H),2.00(s,3H),1.89(s,3H),1.77(s,3H).

[0110] Example 9: Synthesis of 5-Fam-CPMB-0013 Step 1: Synthesis of CPMB-0013-A An exemplary synthetic scheme for producing CPMB-0013A is provided in FIG. 2A.

[0111] To a solution of (6-(3-((2S,5S,11S,17S)-5,11,17-tris(4-aminobutyl)-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexazacyclooctadecan-2-yl)propanamido)hexyl)carbamate (CPMB-001) (898 mg, 747 μmol, 1.0 equiv.) in DMF (5 mL), was added EDCI HCl (859 mg, 4.48 The resulting solution was stirred at 25 °C overnight and monitored by LCMS. Upon completion, the solution was diluted with HO (15 mL), extracted with DCM (3 x 20 mL), dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by reverse phase chromatography eluting with HO (0.01% v / v TFA) / MeCN (95 / 5 to 5 / 95) to give compound CPMB-0013-A as a white foam (1.22 g, 78% yield).

[0112] Purification method: Mobile phase: A: 0.05% TFA in water; B: 0.05% TFA in acetonitrile Column: Waters XBridge Prep C18, 19 x 250 mm, 10 μm, 110A Flow rate: 25mL / min Eluent: Elution with a linear density gradient of A / B = 71 / 29 to 61 / 39 (20 min) LCMS: (ESI) m / z=1053.3 [M / 2+H] + .

[0113] Step 2: Synthesis of 5-Fam-CPMB-0013 An exemplary synthetic scheme for producing 5-Fam-CPMB-0013 is provided in FIG. 2B.

[0114] To a solution of CPMB-0013-A (14.3 mg, 6.8 μmol, 1.0 equiv) in MeOH (2.0 mL) was added Pd / C (4.0 mg, 10.0%). The flask was evacuated and flushed with H2 three times. The resulting mixture was stirred at 25° C. for 16 h and monitored by LCMS. Upon completion, the mixture was filtered through a syringe equipped with a filtration membrane (0.5 μm, NAVIGATOR®). To the filtrate was added a solution of NaOMe in MeOH (100 μL, 30.0 wt %, 5.4 M). The resulting solution was stirred at 25° C. for 20 min and monitored by LCMS. Upon completion, the solution was neutralized by adding acetic acid (31.0 μL). The solution was concentrated in vacuo and the residue was dissolved in saturated aqueous NaHCO3 (1 mL) and diluted with HO (1.0 mL) before adding 2,5-dioxopyrrolidin-1-yl 3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylate (5FAM-OSu, 4.8 mg, 10.2 μmol, 1.5 equiv.). The flask was covered with aluminum foil to protect the solution from light. The resulting solution was stirred at 25 °C for 16 h and monitored by LCMS. Upon completion, the solution was diluted with MeCN (2.0 mL) and purified by preparative HPLC to give 5-Fam-CPMB-0013 as an orange solid (5.0 mg, 38% yield).

[0115] Purification method: Mobile phase: A: 0.05% TFA in water; B: 0.05% TFA in acetonitrile Column: Phenomenex Gemini C18, 21.2 x 250 mm, 10 μm, 110A Flow rate: 25mL / min Eluent: Elution with linear density gradient of A / B = 84 / 16 to 74 / 26 (20 min)

[0116] LCMS: (ESI) m / z=976.2[M+2H] / 2 + . HPLC: 97.57% (214nm), room temperature = 12.776 minutes Mobile phase: A: Water (0.05%TFA) B: ACN (0.05%TFA)

[0117] Gradient: 5% B for 3 min, increasing to 65% B within 20 min, increasing to 95% within 2 min, holding for 5 min, and returning to 5% B within 0.1 min. Flow rate: 1.0mL / min Column: XBridge Peptide BEH Column C18, 4.6 x 150 mm, 3.5 μm, 130A Column temperature: 20℃

[0118] Example 10: Synthesis of CPMB-0013 An exemplary synthetic scheme for producing CPMB-0013 is provided in FIG.

[0119] To a solution of CPMB-0013-A (695 mg, 0.33 mmol, 1.0 equiv) in MeOH (20.0 mL) was added Pd / C (0.18 g, 10.0%). The flask was evacuated and flushed with H2 three times. The resulting mixture was stirred at 25° C. for 16 h and monitored by LCMS. Upon completion, the mixture was filtered and concentrated. The residue was dissolved in 10 mL of DMF and EDCI·HCl (94.8 mg, 0.49 mmol, 1.5 equiv), HOAt (67.3 mg, 0.49 mmol, 1.5 equiv), DIPEA (173 μL, 1 mmol, 3.0 equiv), and 4-((2S,4R)-4-acetoxy-2-(acetoxymethyl)pyrrolidin-1-yl)-4-oxobutanoic acid (4-((2S,4R)-4-acetoxy-2-(acetoxymethyl)pyrrolidin-1-yl)-4-oxobutanoic acid: 119.2 mg, 0.39 mmol, 1.2 equiv) were added in sequence. The reaction was stirred at room temperature for 3 h and monitored by LCMS. After completion of the reaction, the mixture was directly purified by reverse phase chromatography eluting with HO (0.01% v / v TFA) / MeCN (95 / 5 to 5 / 95) to give compound CPMB-0013-D as a white powder (0.65 g, 87% yield).

[0120] Compound CPMB-0013-D (0.65 g, 0.29 mmol, 1.0 equiv) was dissolved in 20 mL of MeOH and a solution of NaOMe in MeOH (30 wt%, 500 μL) was added. The solution was stirred at room temperature for 20 min and LCMS showed that the deacetylation process was complete. Acetic acid (155 μL) was then added to the mixture to neutralize the solution. The mixture was diluted with water (15 mL) and purified by preparative HPLC eluting with HO (10 mmol of NHOAc) / MeCN to give 280 mg of the desired compound CPMB-0013 as a white foam. (Yield 54%)

[0121] Purification method: Mobile phase: A: 10 mmol of NHOAc; B: ACN Column: Waters XBridge Prep C18, 19 x 250 mm, 10 μm, 130A Flow rate: 25mL / min Elution with a linear density gradient of A / B = 95 / 5 to 85 / 15 (20 min), the fraction at 20.92 min was collected and lyophilized. LCMS:(ESI)m / z=795.7[(M-GalNAc) / 2+H] + HPLC:90.04%(214nm), room temperature=12.28 minutes Mobile phase: A: Water (0.01%TFA) B: ACN (0.01%TFA) Gradient: 2% B for 4 min, increasing to 32% B within 15 min, increasing to 95% B within 3 min, holding for 5 min, and returning to 5% B within 0.1 min. Flow rate: 1mL / min Column: XBridge Peptide BEH C18, 4.6 x 150 mm, 3.5 μm, 130A Column temperature: 40℃

[0122] Example 11: Synthesis of CPMB-0013-DMTr An exemplary synthetic scheme for producing CPMB-0013-DMTr is provided in FIG.

[0123] Step 1: Synthesis of CPMB-0013-F To a solution of CPMB-0013-A (210 mg, 0.10 mmol, 1.0 equiv) in MeOH (20.0 mL) was added Pd / C (50 mg, 10.0%). The flask was evacuated and flushed with H2 three times. The resulting mixture was stirred at 25 °C for 16 h and monitored by LCMS. Upon completion, the mixture was filtered through a syringe equipped with a filtration membrane (0.5 μm, NAVIGATOR®). The residue was dissolved in 1 mL of DMF and EDCI·HCl (28.6 mg, 0.15 mmol, 1.5 equiv), HOAt (20.3 mg, 0.15 mmol, 1.5 equiv), DIPEA (52 μL, 0.30 mmol, 3.0 equiv), and Int-DMTr (84.6 mg, 0.12 mmol, 1.2 equiv) were added in sequence. The reaction was stirred at room temperature for 3 hours and monitored by LCMS. After completion of the reaction, the mixture was directly purified by reverse phase chromatography eluting with H2O (0.01% v / v NH4HCO3) / MeCN (95 / 5 to 5 / 95) to give compound CPMB-0013-F as a white powder (177 mg, 67% yield).

[0124] Purification method: Mobile phase: A: 10 mmol of NHOAc; B: ACN Column: Waters XBridge Prep C18, 19 x 250 mm, 10 μm, 130A Flow rate: 25mL / min Elution with a linear density gradient of A / B = 56 / 44 to 46 / 54 (20 min), the fraction at 19.52 min (100%) was collected and lyophilized. LCMS:(ESI)m / z=1181.4[(M-DMTr) / 2+H] +

[0125] Step 2: Synthesis of CPMB-0013-DMTr To a solution of CPMB-0013-F in MeOH / EtOAc (20.0 mL, 1:1) was added Pd / C (40 mg, 10.0%). The flask was evacuated and flushed with H2 three times. The suspension was stirred at 25 °C for 6 h and monitored by LCMS. Upon completion, the solution was filtered and concentrated in vacuo. The residue was purified by preparative HPLC eluting with H2O (0.01% v / v NH4HCO3) / MeCN (95 / 5 to 5 / 95) to give 33 mg of the desired compound CPMB-0013-DMTr as a white powder. (Yield 19%)

[0126] Purification method: Mobile phase: A: 10 mmol of NHOAc; B: ACN Column: Waters XBridge Prep C18, 19 x 250 mm, 10 μm, 130A Flow rate: 25mL / min Elution with a linear density gradient of A / B = 68 / 32 to 58 / 42 (20 min), a fraction (98.4%) was collected at 15.65 min and lyophilized. LCMS: (ESI) m / z=1285.6 [M / 2-H] - . HPLC:>99%(214nm), room temperature=10.58 minutes Mobile phase: A: Water (10 mM NH4HCO3) B: ACN Gradient: 5% B for 1 min, increasing to 95% B within 20 min, increasing to 95% B for 5 min, and returning to 5% B within 0.1 min. Flow rate: 1mL / min Column: XBridge Peptide BEH C18, 4.6 x 150 mm, 3.5 μm, 130A Column temperature: 40℃

[0127] Example 12: Synthesis of CPMB-0013-DT MR-PEG4-CPG resin Step 1: Synthesis of CPG-PEG4 An exemplary synthetic scheme for producing CPG-PEG4 is provided in FIG. 5A.

[0128] Shake CPG resin (488 mg, 35-50 μmol / g), 1-(9H-fluoren-9-yl)-3-oxo-2,7,10,13,16-pentaoxa-4-azaoctadecan-18-oic acid (FmocNH-PEG4-CH2COOH) (23 mg, 48.8 μmol, 2.0 equiv.), DIPEA (17 μL, 97.6 μmol, 4.0 equiv.), HOBt (6.6 mg, 48.8 μmol, 2.0 equiv.), and HBTU (18.5 mg, 48.8 μmol, 2.0 equiv.) in DMF (2 mL) at room temperature for 24 h. Then, wash the resin with DMF (3 mL x 3). Kaiser test negative. Then, wash the resin with MTBE (5 mL x 3) and dry in vacuum. Filling test: 6.1 mg, 8.0 mg, and 12.0 mg of CPG resin (m CPG ) and add 1 mL of DBU (2% in DMF) to each tube. After 30 min, transfer 800 μL of the supernatant to a 25 mL volumetric flask and fill the flask with MeCN. 304nm ) absorbance: 0.069, 0.091, 0.138. Therefore, the filling is average*4.1 / m CPG = 47 μmol / g, >99% yield.

[0129] Step 2: Synthesis of CPG-PEG4-CPMB-0013-DMTr An exemplary synthetic scheme for producing CPG-PEG4-CPMB-0013-DMTr is provided in FIG. 5B.

[0130] CPG-PEG4 resin (150 mg, 47 μmol / g) is shaken in 3 mL of DBU (2% in DMF) for 1 h. Kaiser test indicates that the de-Fmoc process is complete, then the resin is washed with DMF (3 mL x 3). CPMB-0013-DMTr (27 mg, 10.5 μmol, 1.5 equiv.), DIPEA (3.6 μL, 10.5 μmol, 3.0 equiv.), HOBt (1.4 mg, 10.5 μmol, 1.5 equiv.), and HBTU (4 mg, 10.5 μmol, 1.5 equiv.) are shaken in DMF (2 mL) at room temperature for 24 h. The resin is then washed with DMF (3 mL x 3). The resin is charged with pyridine / Ac2O (1 mL / 20 μL) and shaken for 1 h. The resin was then washed with DMF (3 mL x 3) and MTBE (5 mL x 3) and dried under vacuum. Loading test: Take 2.7 mg of CPG-PEG4-CPMB-0013-DMTr resin and add 200 μL of 1N HCl and 200 μL of MeCN. LCMS: S(DMTr + ) = 691.54 mAU, loading = 32 μmol / g, 51.6 mg.

[0131] Example 13: Synthesis of 5-Fam-CPMB-0023 Step 1: Synthesis of CPMB-0023-A An exemplary synthetic scheme for producing CPMB-0023-A is provided in FIG. 6A.

[0132] To a solution of (6-(3-((2R,5R,11R,17R)-5,11,17-tris(4-aminobutyl)-3,6,9,12,15,18-hexaoxo-1,4,7,10,13,16-hexazacyclooctadecan-2-yl)propanamido)hexyl)carbamate (CPMB-002) (904 mg, 752 μmol, 1.0 equiv.) in DMF (5 mL), was added EDCI HCl (865 mg, 4.51 The resulting solution was stirred at 25 °C overnight and monitored by LCMS. Upon completion, the solution was diluted with HO (15 mL), extracted with DCM (3 x 20 mL), dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by reverse phase chromatography eluting with HO (0.01% v / v TFA) / MeCN (95 / 5 to 5 / 95) to give compound CPMB-0023-A as a white foam (1.49 g, 94% yield).

[0133] Purification method: Mobile phase: A: 0.05% TFA in water; B: 0.05% TFA in acetonitrile Column: Waters XBridge Prep C18, 19 x 250 mm, 10 μm, 110A Flow rate: 25mL / min Elution with a linear density gradient of A / B = 71 / 29 to 61 / 39 (20 min), the fraction was collected at 18.35 min and lyophilized. LCMS: (ESI) m / z=1053.3 [M / 2+H] + .

[0134] Step 2: Synthesis of 5-Fam-CPMB-0023 An exemplary synthetic scheme for producing 5-Fam-CPMB-0023 is provided in FIG. 6B.

[0135] To a solution of CPMB-0023-A (17.0 mg, 8.1 μmol, 1.0 equiv) in MeOH (2.0 mL) was added Pd / C (4.0 mg, 10.0%). The flask was evacuated and flushed with H2 three times. The resulting mixture was stirred at 25° C. for 16 h and monitored by LCMS. Upon completion, the mixture was filtered through a syringe equipped with a filtration membrane (0.5 μm, NAVIGATOR®). To the filtrate was added a solution of NaOMe in MeOH (100 μL, 30.0 wt %, 5.4 M). The resulting solution was stirred at 25° C. for 20 min and monitored by LCMS. Upon completion, the solution was neutralized by adding acetic acid (31.0 μL). The solution was concentrated in vacuo and the residue was dissolved in saturated aqueous NaHCO3 (1 mL) and diluted with HO (1.0 mL) before adding 2,5-dioxopyrrolidin-1-yl 3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylate (5.7 mg, 12.1 μmol, 1.5 equiv). The flask was covered with aluminum foil to protect the solution from light. The resulting solution was stirred at 25°C for 16 h and monitored by LCMS. Upon completion, the solution was diluted with MeCN (2.0 mL) and purified by preparative HPLC to give 5-Fam-CPMB-0023 as an orange solid (8.5 mg, 54% yield).

[0136] Purification method: TFA buffers are used: A: 0.05% TFA in water; B: 0.05% TFA in acetonitrile. Column: Phenomenex Gemini C18, 21.2 x 250 mm, 10 μm, 110A Flow rate: 25mL / min Elution with a linear density gradient of A / B = 83 / 17 to 73 / 27 (20 min), the fraction was collected at 17.85 min and lyophilized. LCMS: (ESI) m / z=976.7 [M / 2+H] + . HPLC:98.15%(214nm), room temperature=12.866 minutes Mobile phase: A: Water (0.01%TFA) B: ACN (0.01%TFA) Gradient: 5% B for 3 min, increasing to 65% B within 20 min, increasing to 95% within 2 min, holding for 5 min, and returning to 5% B within 0.1 min. Flow rate: 1.0mL / min Column: XBridge Peptide BEH Column C18, 4.6 x 150 mm, 3.5 μm, 130A Column temperature: 20℃

[0137] Example 14: Synthesis of CPMB-0023 An exemplary synthetic scheme for producing CPMB-0023 is provided in FIG.

[0138] Step 1: Synthesis of CPMB-0023-D To a solution of CPMB-0023-A (294 mg, 0.14 mmol, 1.0 equiv) in MeOH (10.0 mL) was added Pd / C (60 mg, 10.0%). The flask was evacuated and flushed with H2 three times. The resulting mixture was stirred at 25° C. for 16 h and monitored by LCMS. Upon completion, the mixture was filtered and concentrated. The residue was dissolved in 2 mL of DMF, and EDCI·HCl (38.8 mg, 0.20 mmol, 1.5 equiv), HOAt (27.2 mg, 0.20 mmol, 1.5 equiv), DIPEA (70 μL, 0.41 mmol, 3.0 equiv), and 4-((2S,4R)-4-acetoxy-2-(acetoxymethyl)pyrrolidin-1-yl)-4-oxobutanoic acid (48.8 mg, 0.16 mmol, 1.2 equiv) were added sequentially. The reaction was stirred at room temperature for 3 h and monitored by LCMS. After completion of the reaction, the mixture was directly purified by reverse phase chromatography eluting with HO (0.01% v / v TFA) / MeCN (95 / 5 to 5 / 95) to give compound CPMB-0023-D as a white powder. (303 mg, 96% yield). LCMS: (ESI) m / z=1128.2 [M / 2+H] + .

[0139] Step 2: Synthesis of CPMB-0023 Compound CPMB-0023-D (303 mg, 0.13 mmol, 1.0 equiv) was dissolved in 5 mL of MeOH and a solution of NaOMe in MeOH (30 wt%, 200 μL) was added. The solution was stirred at room temperature for 20 min and LCMS showed that the deacetylation process was complete. Acetic acid (62 μL) was then added to the mixture to neutralize the solution. The mixture was diluted with water (15 mL) and purified by preparative HPLC eluting with HO (10 mmol NHOAc) / MeCN to give 98 mg of the desired compound CPMB-0023 as a white foam. (Yield 42%)

[0140] Purification method: TFA buffers are used: A: 0.05% TFA in water; B: 0.05% TFA in acetonitrile. Column: Welch Topsil C18, 21.1 x 250 mm, 5 μm, 150A Flow rate: 25mL / min Elution with a linear density gradient of A / B = 95 / 5 to 85 / 15 (20 min), the fraction at 20.77 min was collected and lyophilized. LCMS:(ESI)m / z=795.6[(M-GalNAc) / 2+H] + . HPLC: 93.66% (214nm), room temperature = 14.31 minutes Mobile phase: A: 0.05% TFA in water B: 0.05% TFA in ACN Gradient: 2% B for 3 min, increasing to 32% B within 20 min, increasing to 95% B within 1 min, held for 6 min, and returning to 2% B within 0.1 min. Flow rate: 1.0mL / min Column: XBridge Peptide BEH Column C8, 4.6 x 50 mm, 3.5 μm, 130A Column temperature: 45℃

[0141] Example 15: Synthesis of CPMB-0023-DMTr An exemplary synthetic scheme for producing CPMB-0023-DMTr is provided in FIG.

[0142] Step 1: Synthesis of CPMB-0023-F To a solution of CPMB-0023-A (206 mg, 0.10 mmol, 1.0 equiv) in MeOH (20.0 mL) was added Pd / C (50 mg, 10.0%). The flask was evacuated and flushed with H2 three times. The resulting mixture was stirred at 25 °C for 16 h and monitored by LCMS. Upon completion, the mixture was filtered through a syringe equipped with a filtration membrane (0.5 μm, NAVIGATOR®). The residue was dissolved in 1 mL of DMF and EDCI·HCl (28.1 mg, 0.15 mmol, 1.5 equiv), HOAt (20.0 mg, 0.15 mmol, 1.5 equiv), DIPEA (52 μL, 0.30 mmol, 3.0 equiv), and Int-DMTr (83.4 mg, 0.12 mmol, 1.2 equiv) were added in sequence. The reaction was stirred at room temperature for 3 hours and monitored by LCMS. After completion of the reaction, the mixture was directly purified by reverse phase chromatography eluting with H2O (0.01% v / v NH4HCO3) / MeCN (95 / 5 to 5 / 95) to give compound CPMB-0023-F as a white powder (114 mg, 44% yield).

[0143] Purification method: Mobile phase: A: 10 mmol of NHOAc; B: ACN Column: Waters XBridge Prep C18, 19 x 250 mm, 10 μm, 130A Flow rate: 25mL / min Elution with a linear density gradient of A / B = 56 / 44 to 46 / 54 (20 min), the fraction at 19.22 min (100%) was collected and lyophilized. LCMS:(ESI)m / z=1181.4[(M-DMTr) / 2+H] + .

[0144] Step 2: Synthesis of CPMB-0023-DMTr To a solution of CPMB-0023-F (114 mg, 0.043 mmol, 1.0 equiv) in MeOH / EtOAc (20.0 mL, 1:1) was added Pd / C (30 mg, 10.0%). The flask was evacuated and flushed with H2 three times. The suspension was stirred at 25 °C for 6 h and monitored by LCMS. Upon completion, the solution was filtered and concentrated in vacuo. The residue was purified by preparative HPLC eluting with H2O (0.01% v / v NH4HCO3) / MeCN (95 / 5 to 5 / 95) to give 79 mg of the desired compound CPMB-0023-DMTr as a white powder. (Yield 72%)

[0145] Purification method: Mobile phase: A: 10 mmol of NHOAc; B: ACN Column: Waters XBridge Prep C18, 19 x 250 mm, 10 μm, 130A Flow rate: 25mL / min Elution with a linear density gradient of A / B = 70 / 30 to 60 / 40 (20 min), a fraction (99.1%) was collected at 19.22 min and lyophilized. LCMS: (ESI) m / z=1285.3 [M / 2-H] - . HPLC:>99%(214nm), room temperature=10.56min Mobile phase: A: Water (10 mM NH4HCO3) B: ACN Gradient: 5% B for 1 min, increasing to 95% B within 20 min, increasing to 95% B for 5 min, and returning to 5% B within 0.1 min. Flow rate: 1mL / min Column: XBridge Peptide BEH C18, 4.6 x 150 mm, 3.5 μm, 130A Column temperature: 45℃

[0146] Example 16: Synthesis of CPMB-0023-DT MR-PEG4-CPG resin An exemplary synthetic scheme for producing CPMB-0023-DTMart-PEG4-CPG resin is provided in FIG.

[0147] CPG-PEG4 resin (100 mg, 47 μmol / g) is shaken in 3 mL of DBU (2% in DMF) for 1 h. Kaiser test indicates that the de-Fmoc process is complete, then the resin is washed with DMF (3 mL x 3). CPMB-0023-DMTr (18 mg, 7 μmol, 1.5 equiv), DIPEA (2.4 μL, 7 μmol, 3.0 equiv), HOBt (0.9 mg, 7 μmol, 1.5 equiv), and HBTU (2.7 mg, 7 μmol, 1.5 equiv) are shaken in DMF (2 mL) at room temperature for 24 h. The resin is then washed with DMF (3 mL x 3). The resin is charged with pyridine / Ac2O (1 mL / 20 μL) and shaken for 1 h. The resin is then washed with DMF (3 mL x 3) and MTBE (5 mL x 3) and dried in vacuum. Loading test: Take 1.5 mg of CPG-PEG4-CPMB-0023-DMTr resin and add 100 μL of 1N HCl and 100 μL of MeCN. LCMS: S(DMTr + )=785.43mAU, loading=31μmol / g, 69mg.

[0148] Example 17: Cellular uptake of cyclic peptides conjugated with Tri-GalNAc Human hepatocellular carcinoma (HepG2) cell line was purchased from Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd. and maintained in minimum essential medium (Gibco, ThermoFisher Scientific, USA) containing 10% fetal bovine serum (Gibco, ThermoFisher Scientific, USA), 200 units / mL penicillin + 200 units / mL streptomycin at 37°C and 5% CO2.

[0149] Cells were plated at 1.5 x 10 per well. 5Cells were seeded in 24-well plates with a density of 1000 x 1000 and incubated at 37°C under 5% CO2. After 18 h of incubation, the medium was replaced with MEM containing 2% FBS, and FAM-labeled ligands were added at final concentrations of 1.6, 8, 40, or 200 nM. After 24 h of incubation, cells were washed twice with 1x PBS and analyzed by LSRFortessa (BD Biosciences, NJ, USA). Binding efficiency was evaluated by the percentage of FAM-positive cells.

[0150] Table 4 below shows the percentage of ligand-bound HepG2 cells. HepG2 cells were treated with 14 cyclic peptide-tri-GalNAc ligand variants with serial dilution concentrations of 1.6, 8, 40, or 200 nM. Commercially available tri-GalNAc used in Givosirna was used as a positive control, and cyclic peptide without tri-GalNAc was used as a negative control. Among the 14 variants, 5-FAM-CPMB-0013 (ID013), 5-FAM-CPMB-0023 (ID023), and 5-FAM-CPMB-0035 (ID035) had relatively high binding ability compared with others and commercial tri-GalNAc. The equilibrium dissociation constants (kd) for 5-FAM-CPMB-0013 (ID013), 5-FAM-CPMB-0023 (ID023), 5-FAM-CPMB-0035 (ID035), and commercial tri-GalNAC were 7.0, 8.6, 5.7, and 18 nM, respectively. [Table 4]

[0151] Example 18: Stability assay of cyclic peptides conjugated with tri-GalNAc The cytotoxic effect of cyclic peptide-tri-GalNAc was evaluated by the viability of HepG2 cells and analyzed by Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories, Japan). The assay was performed according to the manufacturer's protocol. Briefly, HepG2 cells were cultured at 6 × 10 per well.4 Cells were seeded in 96-well plates with a density of 1000 μg / well and incubated at 37°C with 5% CO2. When the cells reached 70% confluence, the medium was changed to MEM containing 2% FBS and treated with serially diluted cyclic peptide-tri-GalNAc at final concentrations of 50, 25, 12.5, 6.25, 3.125, and 1.5625 μM. After 24 h of treatment, 10 μL of CCK-8 solution was added to each well and incubated at 37°C for 1 to 4 h. The absorbance at 450 nm was measured by a microplate reader (Thermo scientific, Multiskan sky, MA, USA). The viability of cells treated with ID013, ID023, and commercial tri-GalNAC is 97 to 100%.

[0152] FAM-labeled tri-GalNAc ligand was prepared in sterile water at a final concentration of 200 nM. 10 μl of ligand was mixed with 90 μl of human plasma and incubated at 37° C. for 0, 24, 48, and 72 hours. At the end of the incubation, 300 μl of methanol was added to each mixture to quench the reaction. The quenched samples were centrifuged at 20,000×g for 5 min, and the supernatant was further filtered through a 0.45 μm filter (Merck Millipore) to remove debris. The filtered samples were measured by UPLC-FLR detector (Waters, MA, USA).

[0153] FIG. 10 shows the results of stability assay of 5-FAM-CPMB-0013 (ID013), 5-FAM-CPMB-0023 (ID023), and commercial tri-GalNAC. 5-FAM-CPMB-0013 (ID013), 5-FAM-CPMB-0023 (ID023), and commercial tri-GalNAC were incubated with 90% human plasma for different time points. The amount of each ligand was analyzed and quantified by UPLC system. According to the data, 5-FAM-CPMB-0013 (ID013), 5-FAM-CPMB-0023 (ID023), and commercial tri-GalNAC were all very stable within 6 hours and then gradually decreased. After 72 h of incubation, the remaining amounts of 5-FAM-CPMB-0013 (ID013), 5-FAM-CPMB-0023 (ID023), and commercial tri-GalNAC were 92.7%, 85.8%, and 79.1%, respectively.

[0154] Example 19: Endosomal escape assay of cyclic peptides conjugated with Tri-GalNAc HepG2 cells, 1 x 10 7 The cells were seeded in 100 mm culture dishes with a density of cells / 10 ml and incubated at 37 °C, 5% CO2. After 18 h of incubation, the culture medium was changed to MEM with 2% FBS containing a final concentration of 1 μM FAM-labeled ligand. After 3 days of treatment, endosomal and cytosolic fractions were separated by Endosome Isolation and Cell Fraction Kit (ED-028, Invent Biotechnologies, USA) according to the manufacturer's protocol. Briefly, 1.5 × 10 5Cells were collected and washed in cold PBS. After centrifugation, the supernatant was completely removed and the pellet was resuspended in 500 μl of buffer A. The cell suspension was then transferred to a filter cartridge and centrifuged at 16,000×g for 30 seconds. The filtrate and pellet were thoroughly mixed by vortexing for 10 seconds and centrifuged at 700×g for 3 minutes to sediment unwanted nuclei and intact cells. The supernatant was transferred to a fresh tube and further centrifuged at 16,000×g for 1 hour at 4°C to sediment unwanted larger organelles and plasma membranes in the pellet. The supernatant was transferred to a new tube, mixed with buffer B in a 1:1 ratio and incubated overnight at 4°C. The mixture was centrifuged at 10,000×g for 30 minutes at 4°C. The supernatant was the cytosolic fraction and the pellet was dissolved in buffer as the endosomal fraction. Fluorescence intensity of the cytosolic and endosomal fractions was determined by a Synergy H1 microplate reader (BioTek, VT, USA) at excitation 490 nm and emission 520 nm.

[0155] Cells were incubated with 5-FAM-CPMB-0013 (ID013), 5-FAM-CPMB-0023 (ID023), and commercial tri-GalNAC, and further fractionated into endosomal and cytosolic fractions. 5-FAM-CPMB-0013 (ID013) and 5-FAM-CPMB-0023 (ID023) were 1.2-fold and 1.6-fold higher in fluorescence intensity than commercial tri-GalNAC in the cytosolic fraction. ID013 and ID023 were 0.7-fold and 0.5-fold lower in fluorescence intensity than commercial tri-GalNAC in the endosomal fraction, confirming that more 5-FAM-CPMB-0013 (ID013) or 5-FAM-CPMB-0023 (ID023) was released from endosomes to the cytosol (see FIG. 11). Therefore, the newly developed cyclic peptide-tri-GalNAc has better ability of endosomal escape.

[0156] Other embodiments All of the features disclosed herein may be combined in any combination. Each feature disclosed herein may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar functionality.

[0157] From the above description, those skilled in the art can easily ascertain the essential features of the present invention, and can make various changes and modifications to the present invention to adapt it to various uses and conditions without departing from the spirit and scope of the present invention. Therefore, other embodiments are also within the scope of the claims.

[0158] Equivalent While several inventive embodiments have been described and illustrated herein, various other means and / or structures for performing the functions described herein and / or obtaining one or more of the results and / or advantages described herein will readily occur to those skilled in the art, and each such variation and / or modification is intended to be within the scope of the inventive embodiments described herein. In general, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are intended to be exemplary, and that the actual parameters, dimensions, materials, and / or configurations will depend on the specific application or applications in which the inventive teachings are used. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific inventive embodiments described herein. Thus, it is understood that the above-described embodiments are presented by way of example only, and that within the scope of the appended claims and their equivalents, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and / or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and / or methods is included within the inventive scope of the present disclosure, if such features, systems, articles, materials, kits, and / or methods are not mutually inconsistent.

[0159] As defined and used herein, all definitions should be understood to take precedence over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.

[0160] All references, patents, and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may include the entire document.

[0161] As used in the specification and claims, the indefinite articles "a" and "an" should be understood to mean "at least one," unless clearly indicated to the contrary.

[0162] As used in the present specification and claims, the phrase "and / or" should be understood to mean "either or both" of the elements so conjoined, i.e., the elements are present conjunctively in some cases and non-conjunctively in other cases. Multiple elements listed with "and / or" should be interpreted in the same manner, i.e., "one or more" of the elements are so conjoined. Other elements other than the elements specifically identified by the "and / or" phrase may optionally be present, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and / or B," when used in conjunction with open-ended language such as "comprising," may refer in one embodiment to only A (optionally including elements other than B), in another embodiment to only B (optionally including elements other than A), in yet another embodiment to both A and B (optionally including other elements), and so forth.

[0163] As used herein and in the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" is interpreted as being inclusive, i.e., including at least one of, but also including two or more of, some elements or lists of elements, and optionally including additional items not listed. Only terms clearly indicated to the contrary, e.g., "only one of," or "exactly one of," or when used in the claims, "consisting of" refers to including exactly one element of, some elements or lists of elements. In general, as used herein, the term "or" is only interpreted as indicating exclusive alternatives (i.e., "one or the other, but not both") when preceded by a term of exclusivity, e.g., "either," "one of," "only one of," or "exactly one of." When used in the claims, "consisting essentially of" has its ordinary meaning as used in the field of patent law.

[0164] As used in this specification and claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed in the list of elements, and not excluding any combination of elements in the list of elements. This definition also allows for elements other than the elements specifically identified in the list of elements and referred to by the phrase "at least one," whether related or unrelated to the elements specifically identified, may optionally be present. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B" or, equivalently, "at least one of A and / or B") can refer to, in one embodiment, at least one, optionally, two or more As, and no B (optionally including elements other than B); in another embodiment, at least one, optionally, two or more Bs, and no A (optionally including elements other than A); in yet another embodiment, at least one, optionally, two or more As, and at least one, optionally, two or more Bs (optionally including other elements); etc.

[0165] Also, unless expressly stated to the contrary, in any method claimed herein that includes two or more steps or actions, it should be understood that the order of the method steps or actions is not necessarily limited to the order in which the method steps or actions are recited.

Claims

1. A conjugate comprising a cyclic peptide scaffold and one or more N-acetylgalactosamine (GalNAc) moieties, the cyclic peptide scaffold has 4 to 10, optionally 4 to 8, amino acid residues including Glu, Asp, Lys, Arg, or a combination thereof; The conjugate, wherein each of the GalNAc moieties is covalently attached to the cyclic peptide scaffold via a first linker.

2. The conjugate of claim 1, further comprising an agent, said agent being covalently attached to said cyclic peptide scaffold via a second linker, and said agent being a therapeutic agent or a diagnostic agent.

3. the cyclic peptide scaffold has six amino acids; and The conjugate of claim 1 , wherein the cyclic peptide scaffold comprises at least one Glu residue and at least one Lys residue.

4. each first linker is covalently attached to said at least one Lys residue; and / or The conjugate of claim 3 , wherein the second linker is covalently attached to the at least one Glu residue.

5. The conjugate of claim 3 , wherein the cyclic peptide scaffold further comprises Gly, Ala, and / or Val.

6. the cyclic peptide scaffold being (a) Lys-Glu-Lys-Gly-Lys-Gly (SEQ ID NO: 5), or (b) the conjugate of claim 1 having an amino acid sequence of Lys-Glu-Lys-Ala-Lys-Ala (SEQ ID NO: 6).

7. The conjugate of claim 6 , wherein one or more amino acid residues in the cyclic peptide scaffold are in the D-form.

8. 2. The conjugate of claim 1, wherein the cyclic peptide scaffold is selected from the group consisting of CPS-001, CPS-002, CPS-003, and CPS-031, or functional equivalents thereof.

9. each first linker comprises a linear chain having 3 to 8 atoms; and 2. The conjugate of claim 1, wherein the 3 to 8 atoms include C, O, or a combination thereof.

10. 10. The conjugate of claim 9, wherein the first linker is a Gal-1, Gal-2, Gal-3, Gal-4, or Gal-5 linker.

11. 3. The conjugate of claim 2, wherein the second linker is a lipid linker, a polyethylene glycol (PEG) linker, or an alkylamine linker.

12. having the structure of formula (I): 【Chemistry 1】 During the ceremony, T is the drug; L １ is the first linker, and the first linker is the linker in Gal-1, Gal-2, Gal-3, Gal-4, or Gal-5; L ２ The conjugate of claim 2 , wherein:

13. having the structure of formula (II): 【Chemistry 2】 During the ceremony, T is the drug; L １ is the first linker, and the first linker is the linker in Gal-1, Gal-2, Gal-3, Gal-4, or Gal-5; L ２ The conjugate of claim 2 , wherein:

14. 2. The conjugate of claim 1, wherein the cyclic peptide scaffold has the amino acid sequence Lys-Glu-Lys-βAla-Lys-βAla (SEQ ID NO: 7).

15. 5-FAM-CPMB-0011, 5-FAM-CPMB-0012, 5-FAM-CPMB-0013, 5-FAM-CPMB-0014, 5-FAM-CPMB-0 015, 5-FAM-CPMB-0021, 5-FAM-CPMB-0023, 5-FAM-CPMB-0025, 5-FAM-CPMB-0031, 5-FAM-CPM 3. The conjugate of claim 2, wherein the conjugate is selected from the group consisting of 5-FAM-CPMB-0033, 5-FAM-CPMB-0034, 5-FAM-CPMB-0035, 5-FAM-CPMB-0311, 5-FAM-CPMB-0313, CPMB-0013, CPMB-0023, CPMB-0013-DOTMr, and CPMB-0023-DOTMr.

16. The conjugate of claim 2 , wherein the drug is a small molecule or a nucleic acid.

17. The conjugate of claim 16 , wherein the drug is a nucleic acid that is an siRNA or a nucleic acid aptamer.

18. A pharmaceutical composition comprising the conjugate of any one of claims 1 to 17 and a pharma- ceutically acceptable excipient.

19. 20. A method of delivering a drug to a liver cell, the method comprising contacting the liver cell with a conjugate according to any one of claims 2 to 17 or a pharmaceutical composition comprising the conjugate, the liver cell being cultured in vitro.

20. A pharmaceutical composition for use in the treatment of liver disease, comprising a conjugate according to any one of claims 2 to 17.

Images